BioMed Protect’s Sanotracin RTU rapidly and effectively kills C. difficile within 3 minutes

In the United States Clostridium difficile or "C. difficile" is now recognized as one of the most dangerous and fastest growing Healthcare Acquired Infections (HAIs) in existence. Now surpassing even Staphylococcus aureus (MRSA), C. difficile infections tripled between 2000 and 2005 (    

BioMed Protect, LLC has announced the introduction of EPA-registered Sanotracin RTU™ ("RTU" meaning ready to use), the effective and affordable surface disinfectant with a three-minute C. difficile spore claim at 99.9999 percent- the fastest efficacy in the industry. Recognized as "the point of protection," patented Sanotracin RTU is proven safe and cost effective with a verified umatched efficacy rate as a bactericide, virucide, tuberculocide, fungicide and sporicidal disinfectant cleaner.

Sanotracin RTU is a hospital-grade disinfectant cleaner for use in all healthcare facilities, including surgical and obstetrical suites, patient rooms, physical therapy departments, nursing services, autopsy facilities and nursing homes.

More importantly, Sanotracin RTU provides sporicidal effectiveness without the use of bleach ( In addition to being the only product with a three-minute efficacy claim, Sanotracin RTU also contains no alcohol, does not require rinsing and leaves no film on surfaces to which it is applied, unlike many competing disinfectants with bleach.

Sanotracin RTU provides environmental services directors and front-line environmental services staff the fastest-acting product to clean and disinfect surfaces exposed to C. difficile spores with maximum efficacy. "As hospitals and healthcare facilities become more efficient in handling HAIs they need the tools and processes in place to provide healthy spaces for patients," said Mark Regna CHESP. Sanotracin RTU disinfectant provides a one-step process to disinfect, eliminate and prevent the spread of C. difficile spores, MRSA, VRE Acinetobacter baumannii and 50 other pathogens.

According to the Centers for Disease Control (CDC), C. difficile infections are linked to 14,000 deaths in the United States each year. Deaths related to C. difficile increased 400% between 2000 and 2007, due in part to a stronger bacterial strain. Most C. difficile infections are contracted by individuals while in the process of receiving medical care. More than 90 percent of deaths occur in people 65 and older ( - gen).

Sanotracin RTU is a critical component in the battle against HAIs because of its rapid, three-minute efficacy. The fatality rate and associated cost make control of C. difficile a grave issue. According to the CDC, in the United States one in 20 hospital-acquired infections is fatal ( Healthcare-associated infections result in associated costs of $35 billion to $45 billion every year through such factors as loss of life, litigation, prolonged hospitalizations and unrecoverable treatment expenses, as has been cited by economist R. Douglas Scott.

Over the past three years, BioMed Protect has devoted its resources to research and development of the Sanotracin RTU formula with improved efficacy and safety for both the healthcare professional and the greater environment as primary goals. The Sanotracin RTU patented formula and process provide an EPA-registered product that cleans and disinfects a broad spectrum of bacteria on hard and non-porous surfaces in two minutes while killing C. difficile in just three minutes - almost twice as fast as any other product.

"At BioMed Protect we are very pleased to announce the revolutionary surface disinfectant Sanotracin RTU, the first EPA-registered surface disinfectant with a three-minute C-diff spore claim," said BioMed Protect CEO Ronald Pass. "BioMed Protect's initiative to bring this disinfectant to fruition has been a three-year project guided by our mission to provide 'Environmental Prevention through Design,' a program to assist the healthcare industry with the right tools and chemicals to reduce HAIs. We believe that Sanotracin RTU provides the correct efficacy and reliability that is needed to assist the healthcare community in the fight against HAIs. We are gratified that BioMed Protect is delivering 21st century technology for 21st century HAIs."


BioMed Protect


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
COVID-19 taking a disproportionate toll on female healthcare workers